Par Pacific Holdings is benefiting from a refining margin super cycle, driving record profits. Find out why PARR stock is a ...

Despite positive interim results in the CAPTIVATE trial, Dianthus faces uncertainty in CIDP, as both drugs target the same ...

Amazon (AMZN) looks like a GARP buy with PEG under 1x and double-digit return potential—driven by AWS, AI, and retail ...

Hershey delivered a Q2 double beat, raised full-year guidance, and now trades at 17.7x 2027 EPS with a 3.32% yield. Read why ...

NVDX achieves 2x daily exposure to NVDA via swap agreements, not by holding the underlying stock. Find out why NVDX ETF is a ...

Everspin is the leading standalone magnetoresistive memory supplier and product demand is accelerating. Find out why MRAM ...

CRISPR Therapeutics' current $5.6B market cap and $1.78B net cash position offer acquisition appeal. Click to know why CRSP ...

Here's a list of key deals reported across sectors this week: ...

TYG offers a 13.27% yield but has significantly underperformed both the energy sector and peer funds year-to-date. Learn why ...

VYM's composition seems to adapt well to the economic context on which the US economy continues to insist. Click for more on ...

Buy XBI? Get outlook for the SPDR S&P Biotech ETF—8%–14% return target, M&A tailwinds, key risks, and volatility factors.

Bristol Myers Squibb's aggressive M&A and in-house R&D efforts have driven the portfolio renewal cadence and ongoing ...